Cowen analyst Phil Nadeau weighed in Zafgen (NASDAQ: ZFGN) announced that a death occurred in its ongoing double-blind, placebo controlled ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Momentum Movers Short Sales Trader Talk

Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death October 16, 2015 1:28 PM Zafgen (ZFGN) PT Lowered to $46 at RBC Capital; Discusses Road Ahead for BeloranibOctober 15, 2015 7:17 AM Zafgen (ZFGN) PT Cut to $48 at FBR Capital on Patient DeathOctober 15, 2015 6:39 AM RBC Sees 33% of Zafgen (ZFGN) Death Happening in Placebo Arm; Reiterates 'Outperform' RatingOctober 14, 2015 2:48 PM Leerink Partners Comments on Zafgen (ZFGN) Following Patient DeathOctober 14, 2015 2:26 PM Zafgen (ZFGN) Worst Case Scenario Avoided, RBC Capital - BloombergOctober 14, 2015 1:18 PM Who Traded Zafgen (ZFGN) on Illegal Insider Information?October 14, 2015 12:54 PM Zafgen (ZFGN) Learns of Death in Beloranib Phase 3October 14, 2015 12:27 PM